- Article
The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
- Ganghee Chae,
- Aram Choi,
- Soyeoun Lim,
- Sooneun Park,
- Seungjun Lee,
- Youngick Ahn,
- Jinhyoung Kim,
- Seungwon Ra,
- Yangjin Jegal and
- Taehoon Lee
- + 4 authors
Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against s...

